Supplementary Figure S14 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Supplementary Figure S14. Overexpression of SB9(CAS) in ‘donor’ CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs increases resistance to allorejection in a B-ALL allorejection model in which ‘donor’ CAR T cell and ‘recipient’ cell levels were quantified via IVIS imaging and flow cytometry, respectively. A, Manufacturing timeline for the generation of CD30.bb EBVSTs expressing eGFP-ffLuc. B, Schematic of in-vivo allorejection model for (C-D), where 2.5 x 106 HLADKO NALM6-CD30 tumor cells were injected intravenously into NSG (MHCKO) mice. 18 days later, 5 x 106 ‘donor’ eGFP-ffLuc-expressing CD30.bb EBVSTs with or without 5 x 106 ‘recipient’ CD30KO Allo-T cells were co-infused intravenously. C, Bioluminescent images of CD30.bb EBVST FFluc+ in NSG (MHCKO) mice bearing HLADKO NALM6-CD30 tumors, with or without the presence of Allo-T cells, at specified time points. D, Quantified bioluminescence of unmodified CD30.bb EBVSTs in the presence (black lines) or absence (grey lines) of Allo-T cells in individual mice at specified time points, (n = 11 for CD30.bb-treated group and n = 12 for CD30.bb + Allo-T treated group). The same data for unmodified ‘donor’ CD30.bb EBVSTs in the presence of ‘recipient’ Allo-T is represented in both (D) and (Fig. 3I). The graphs denote mean + SD.